Inhalerx Limited

Clinical Development Outlook 2026 Presentation Slides

This is a clinical development outlook presentation for InhaleRx Limited (rebranding to Nexalis Therapeutics, ASX:NX1), which is developing three drug candidates for pain management and mental health. The company has secured over $50 million in funding to advance all three programs through clinical trials, with Phase 1 trials for IRX-616a (panic disorder) and first patient dosing for both IRX-211 (breakthrough cancer pain) and IRX-616a expected in Q1 2026. Key points: Over $50 million secured for clinical development plans across all three programs; Two HREC approvals secured with both IRX-211 and IRX-616a trials ready to commence; IRX-211 Phase 1 trial completed with very promising insights and no serious adverse events